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Protein kinase C activators (e.g. PMA) inhibit the inositol phosphate release generated by crosslinking antigen receptors 
(sIgM and sIgD) on murine B lymphocytes with anti-receptor antibodies. Unlike other Ca2+-mobilizing receptor systems, 
the antigen receptor signal transduction pathway in B cells is not interrupted by PMA at the level of receptor/G-protein 
or G-protein/polyphosphoinositide phosphodiesterase coupling. In these cells, PMA, presumably by activating protein 
kinase C, inhibits inositol phosphate release by direct effects on the polyphosphoinositide-specific phosphodiesterase. 
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1. INTRODUCTION 
Crosslinking of surface immunoglobulin (slg) 
receptors by anti-Ig antibodies activates essentially 
all quiescent B lymphocytes and causes a substan- 
tial proportion of them to synthesize DNA [ 1,2]. 
Ligation of these antigen receptors provokes the 
rapid hydrolysis of phosphatidylinositol 4,5-bis- 
phosphate (PIPz) to inositol trisphosphate (IP3) 
and diacylglycerol (DAG) [3,4]. Generation of 
these second messengers leads to the mobilization 
of intracellular Ca2+ stores [5] and the activation 
of protein kinase C (PKC) [6]. 
PKC-activating phorbol esters (e.g. PMA) in- 
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hibit anti-Ig-induced B cell activation [7,8]. 
However, these agents can also stimulate DNA 
synthesis in lymphocytes, either alone or in synergy 
with other stimuli [9,10]. The inhibitory effects of 
phorbol esters on anti-Ig-induced B cell activation 
correlate with their capacity to suppress receptor- 
stimulated PIP2 hydrolysis and Ca2+ mobilization 
[8,1 l-l 31. These findings support the concept of 
PKC-mediated feedback inhibition of receptor- 
directed inositol phosphate production proposed 
for other Ca2+-mobilizing systems (e.g. [14-171). 
It has recently become evident that sIgM and 
sIgD receptors on B lymphocytes, in common with 
many other Ca2+ -mobilizing receptors, are coupled 
to the polyphosphoinositide-specific phosphodies- 
terase (PPI-PDE) via a G-protein termed G, 
[ 18,191. Such a signalling cascade provides several 
potential sites of regulation: at the level of ligand- 
receptor interaction, receptor/G-protein coupling, 
G-protein/PPI-PDE coupling or at the level of 
PPI-PDE itself. We here demonstrate that PKC 
activators, such as PMA, inhibit signalling via the 
antigen receptors on B cells by direct inhibition of 
PPI-PDE activity. 
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2. MATERIALS AND METHODS 
2.1. Reagents 
myo-[3H]lnositol (spec. act. 110 Ci/mmol) was from Amer- 
sham International (Amersham, England). GTP+ was from 
BCL (Lewes, Sussex, England). Protease inhibitors and phor- 
bol esters were from Sigma (Poole, Dorset, England). Reduced 
streptolysin-0 was from Wellcome Diagnostics (Beckenham, 
Kent, England). Monoclonal rat anti-mouse p (anti-p; b.7.6) 
and mouse anti-lgh-5a (antid; AMS28.11) were purified as 
described in [18]. 
2.2. Assay of inositol phosphate release 
Briefly, splenic B cells were purified from CBA/Ca (Igh-Sa) 
mice and labelled with [3H]inositol (0.5-2.5 &i/lo6 cells) as 
previously described [18]. The cells were then washed and 
resuspended at 20 x lo6 cells/ml in the permeabilization buffer 
(adjusted to 10 nM Ca’+ with CaEGTA buffers) described in 
[18]. After equilibration at 37°C for 10 min, the cells were in- 
cubated in the presence and absence of PMA for 10 min. 
Reduced streptolysin-0 (0.5 IU/ml: final cont.) was added and 
after 5 min the permeabilized cells were diluted two-fold (final 
volume 300 al) into tubes containing Ca2+ (buffered with 3 mM 
EGTA), anti-Ig antibodies (50 pg/ml) and GTPyS. After a final 
10 min incubation, the reactions were terminated and the in- 
ositol phosphates were separated [18]. Stimulation of intact 
cells with anti-Ig was carried out in supplemented RPM1 1640 
medium plus 5% (v/v) fetal calf serum. 
3. RESULTS 
Pretreatment of intact B cells with PMA effec- 
tively blocked the generation of inositol 
phosphates induced by crosslinking either sIgM or 
sIgD (maximal inhibition at 16 nM) (fig.l), con- 
firming earlier results [8,1 l-131. Moreover, the 
basal rate of inositol phosphate production was 
also suppressed by PMA. Using a permeabilized 
cell system, we have recently reported that both the 
sIgM and sIgD receptors are coupled to the PPI- 
PDE via one or more pertussis toxin-insensitive 
forms of G, [18]. In the present study we have 
therefore used this system to determine at which 
stage in the receptor/G-protein/PPI-PDE sig- 
nalling cascade PMA exerts its inhibitory effects. 
In permeabilized cells, G, can be directly ac- 
tivated by the nonhydrolysable CTP analogue, 
GTPyS. As expected, in B cells this activation is 
markedly augmented by co-stimulation of the cells 
with anti-Ig antibodies (inactive on their own) plus 
GTPyS [ 181. This is because optimal activation of 
the G,-linked PPI-PDE requires its interaction 
with ‘excited’ receptors. Thus, if PMA disrupts the 
G-protein/PPI-PDE coupling, pretreatment of the 
cells with phorbol ester should inhibit GTP+- 
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Fig.1. Inhibition of basal and stimulated (sIgM and sIgD- 
mediated) inositol phosphate release by PMA in intact B cells. 
[3H]Inositol-labelled B cells were preincubated for 10 min with 
a range of PMA concentrations before stimulation with 
medium (0), or with anti-p (0) or anti-d (0) anti-receptor 
antibodies. Total inositol phosphate release was measured after 
IO min. 
induced production of inositol phosphates. On the 
other hand, if PMA inhibits the coupling between 
the antigen receptors and G,, the GTPyS-induced 
inositol phosphate production should be unaf- 
fected, whilst the augmented release in response to 
anti-Ig would be abrogated. 
These two possibilities were tested in the ex- 
periments summarized in fig.2. Pretreatment of B 
cells with 160 nM PMA led to a comparable 
(65-70%) inhibition of the basal, GTPyS- 
stimulated and GTPyS plus anti-Ig-induced pro- 
duction of inositol phosphates (fig.2a) (16 nM 
PMA: 60-65% inhibition; 1.6 nM PMA: 510% 
inhibition, results not shown). Thus, although the 
generation of inositol phosphates was clearly sup- 
pressed by PMA, the stimulation indices 
(calculated as % of the basal rate) of GTPyS and 
GTPyS plus anti-Ig-induced activation were unaf- 
fected. These conclusions were reinforced by the 
results shown in fig.2b, which depicts the effects of 
1.6, 16 or 160 nM PMA on the direct stimulation 
of G, induced by a wide range of GTPyS concen- 
trations. 
These results suggested that in B cells PMA does 
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Fig.2. Effects of PMA pretreatment on the GTPyS and GTPyS 
plus anti-Ig-mediated release of inositol phosphates in 
permeabilized B cells. [3H]Inositol-labelled, permeabilized B 
cells were stimulated with (a) GTPyS (100 ,uM) with or without 
anti-Ig antibodies. Control cells, open bars; cells pretreated 
with 160 nM PMA, shaded bars. (b) Cells were pretreated with 
1.6, 16, or 160 nM PMA and were then stimulated with the 
indicated concentrations of GTPyS. Total [‘Hlinositol 
phosphate release was measured after 10 min. 
not affect receptor/G-protein coupling, or G- 
protein/PPI-PDE coupling, but rather may cause 
direct modification of PPI-PDE itself. In order to 
measure the basal rate of PPI-PDE activity, the 
above experiments were carried out at pCa 7 
(100 nM), i.e. at the levels of intracellular Ca2+ 
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Fig.3. Effects of phorbol esters and diacylglycerol on the 
Ca’+-activated PPI-PDE activity. [3H]Inositol-labelled, 
permeabilized B cells were preincubated with PMA, phorbol 
monomyristate (PMM), phorbol monoacetate (PA) (all at 
160 nM) or 1,2-dicapryloyl-rut-glycerol (DiCs) (160 PM) for 
10 min before stimulation with the indicated Ca’+ buffers. 
Total inositol phosphate release was measured after 10 min. 
pertaining in unstimulated cells. However, PPI- 
PDE can be directly activated by high, non- 
physiological (millimolar) levels of Ca2+. As 
shown in fig.3 the direct activation of PPI-PDE at 
pCa 3 was effectively blocked by 160 nM PMA. 
Furthermore, it is likely that this effect is due to ac- 
tivation of PKC, since the inhibition can be 
mimicked by the metabolizable diacylglycerol, 
1,2-dicapryloyl-rat-glycerol but not by the nonac- 
tive phorbol esters, phorbol monomyristate or 
phorbol monoacetate (fig.3). 
4. DISCUSSION 
The results of this study indicate that activation 
of PKC by agents such as PMA directly inhibits 
the activity of PPI-PDE in B cells. Previous 
workers [B, 1 l-131 had shown that pretreatment of 
B cells and B cell lymphomas with PMA inhibits 
both inositol phosphate generation and in- 
tracellular Ca2+ mobilization induced by crosslink- 
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ing sIg receptors with anti-Ig antibodies. Although 
the precise mechanism had not been defined, it 
seemed likely that these effects were mediated via 
PKC [ 121. It was also clear that the inhibition by 
PMA was not due to (i) down-regulation of sIg 
receptor expression [8,11], (ii) a decrease in 
receptor-binding affinity or in the rate of capping 
[8], nor (iii) a decrease in PIP2 substrate available 
for hydrolysis by PPI-PDE [12,20]. 
Recently, the use of permeabilized cell systems 
has allowed the detection of G, in the sIg recep- 
tor/PPI-PDE signal transduction pathway [ 18,191. 
Coupling of cell surface receptors to their effector 
enzymes (in this case PPI-PDE) by a G-protein 
provides several potential regulatory sites. Our 
results show that with sIg receptors on B cells, 
unlike other Ca2+-mobilizing receptor systems, 
PMA does not interrupt either the receptor/G- 
protein [21-241 or the G-protein/PPI-PDE coupl- 
ing [25-271. Rather, in these cells, PMA and syn- 
thetic DAG inhibit signalling through both sIgM 
and sIgD receptors by affecting the activity of PPI- 
PDE, presumably via activation of PKC. Similar 
results have recently been reported for the f-Met- 
Leu-Phe receptor signalling pathway in HL60 cells 
(Cockcroft, S. et al., personal communication and 
[28]). These results are in line with recent findings 
that both membrane-bound and cytosolic PPI- 
PDE are substrates for PKC [29]. In conclusion, it 
is becoming apparent that activation of PKC can 
exert feedback control on signalling via 
Ca2+-mobilizing receptors at multiple sites. 
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